CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on personalizing treatment for metastatic castration-resistant prostate cancer by exploring the interplay between androgen receptor and DNA damage repair pathways. It aims to identify therapeutic vulnerabilities in patients with specific genetic defects to optimize treatment strategies.
Prostate cancer is the 2nd most common cancer in the western world.
The advanced stage, metastatic castration-resistant prostate cancer (mCRPC), is a lethal disease.
Understanding inter-patient genomic heterogeneity renders the opportunity to advance towards personalised patient care.
Prostate cancer is a disease primarily driven by the androgen receptor (AR) pathway; however, the applicant prior work contributed to identifying 1) that up to 25% of mCRPC harbour defects in DNA damage repair (DDR…
FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
